Loading
Hospitals in the 340B programme buy cancer drugs at steep discounts but usually bill patients and insurers the full price; requiring the discount to reach low-income patients would turn a hospital subsidy into patient relief.
The 340B programme lets qualifying hospitals buy outpatient drugs at discounts of 25% to 50% or more, with no requirement that the saving reach the patient. HRSA reported $66.3 billion of purchases at 340B prices in 2023. A pass-through rule would require covered entities to charge uninsured and under-insured patients no more than the 340B acquisition cost plus a dispensing fee for oncology drugs, with the hospital keeping the margin only on insured patients.
Shares 340B Drug Pricing Program, Financial toxicity, Incentives reward me-too drugs and marginal gains, Prices and value.
Shares 340B Drug Pricing Program, Incentives reward me-too drugs and marginal gains, Prices and value.
Shares Financial toxicity, Prices and value.
Shares Financial toxicity, Prices and value.
Shares Financial toxicity, Prices and value.
Shares Incentives reward me-too drugs and marginal gains, Prices and value.
Shares Incentives reward me-too drugs and marginal gains, Prices and value.
Shares Incentives reward me-too drugs and marginal gains, Prices and value.